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Liver transplantation is currently the only therapeutic option for patients with end-stage chronic liver disease and for severe acute liver failure.
Because of limited donor availability, attention has been focused on the possibility to restore liver mass and function through cell transplantation.
Stem cells are a promising source for liver repopulation after cell transplantation, but whether or not the adult mammalian liver contains hepatic
stem cells is highly controversial. Part of the problem is that proliferation of mature adult hepatocytes is sufficient to regenerate the liver after two-
thirds partial hepatectomy or acute toxic liver injury and participation of stem cells is not required. However, under conditions in which hepatocyte
proliferation is blocked, undifferentiated epithelial cells in the periportal areas, called “oval cells”, proliferate, differentiate into hepatocytes and
restore liver mass. These cells are referred to as facultative liver stem cells, but they do not repopulate the normal liver after their transplantation.
In contrast, epithelial cells isolated from the early fetal liver can effectively repopulate the normal liver, but they are already traversing the hepatic
lineage and may not be true stem cells. Mesenchymal stem cells and embryonic stem cells can be induced to differentiate along the hepatic lineage
in culture, but at present these cells are inefficient in repopulating the liver. This review will characterize these various cell types and compare the
properties of these cells and the conditions under which they do or do not repopulate the liver following their transplantation.
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Stem cells originate from the inner cell mass during devel-
opment of the blastocyst. They are pluripotent and are referred to
as embryonic stem (ES) cells [1]. These cells give rise to somatic
stem cells that differentiate further intomultipotent tissue-specific
stem cells [1–3]. Thesemultipotent tissue-specific stem cells then
give rise to progenitor cells that subsequently proliferate and
differentiate into mature somatic phenotypes that comprise organ
mass (Fig. 1). Stem cells are generally considered to exhibit four
major properties: (1) capacity for self-renewal or self-mainte-
nance (generally slowly cycling); (2) multipotency (capable of
producing progeny in at least two lineages); (3) functional, long-
term tissue reconstitution; and (4) serial transplantability. For
stem cells to maintain themselves in adult tissue and at the same
time provide cells tomaintain the differentiated function(s) of that
tissue, some of the cells must undergo division without differ-
entiation or asymmetric division, such that one of the progeny
remains undifferentiated, while the other proliferates and differ-
entiates to generate new tissue mass [4–6]. Concerning the liver,
Fig. 1. Schematic diagram showing the lineage progression of stem cells in the mammalian blastocyst to adult somatic cells in various tissues.
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vitro with hepatic-derived cell lines [7], but this property has not
been identified in vivo. An alternative method to study self-
maintenance in vivo is to identify “label retaining cells” and
follow their fate after inducing their proliferation and differentia-
tion. Such studies have also been conducted in skin epithelia [8]
but not yet in the liver.
Self-renewal is a property unique to stem cells, whereas
progenitor cells that are the progeny of stem cells also
proliferate and differentiate into somatic populations but do
not maintain themselves. They may have single or multi-lineage
potential, but are capable of only short-term tissue reconstitu-
tion. Progenitor cells have also been well-studied in skin
epithelia and the intestinal tract, where they have also been
termed “transit amplifying cells” [4]. Activated “oval cells”
exhibit many features of “transit amplifying cells” and thus may
represent the counterpart to "transit amplifying" cells in the
liver, where tissue mass turns over very slowly.2. Liver regeneration
In the normal adult liver, hepatocytes are in a quiescent state
and turn over very slowly (1–2 times/year). However, following
two-thirds partial hepatectomy (PH) or acute toxic liver injury
in rodents, the liver regenerates very quickly (within 1–
2 weeks). A similar process occurs in larger animals and in
humans, but at a somewhat slower rate (~1 month). The final
size of the liver is proportional to total body weight (~3.0–3.5%
in rodents); however, the precise mechanism that regulates
hepatic mass has not been determined.
In the 1960s, it was shown in rats that during liver
regeneration, hepatocytes throughout the liver parenchyma are
actively engaged in DNA synthesis, and it was estimated that
70–90% of hepatocytes undergo at least one round of cell
division during this process [9]. However, after two-thirds PH,
only one or two divisions of each remaining hepatocyte is
required to restore liver mass, so that the proliferative response
63M. Oertel, D.A. Shafritz / Biochimica et Biophysica Acta 1782 (2008) 61–74is rather small. Under normal conditions, liver regeneration is
achieved through proliferation of differentiated hepatocytes
(including tetraploid cells) and does not require the participa-
tion of stem cells [10,11]. However, whether stem cells are
involved in normal liver homeostasis or in maintenance of
hepatic mass or function during chronic liver injury has not
been determined.
3. Hepatocytes as liver stem cells?
In the last decade, landmark studies have demonstrated that
hepatocytes, under specialized circumstances, have virtually
unlimited proliferative potential. In urokinase plasminogen ac-
tivator (uPA) transgenic mice, in which host hepatocytes are
continually being destroyed [12], transplanted normal (wt) he-
patocytes undergo more than 12 cell divisions on average and
replace most of the host liver [13]. In fumarylacetoacetate
hydrolase (FAH) knockout mice, a model of Hereditary Tyro-
sinemia Type 1, in which there is also extensive and continuous
liver injury, the metabolic disorder can be corrected by trans-
planting wt hepatocytes, with full restoration of normal lobular
structure and function [14,15]. Using this cell transplantation
model, Grompe et al. demonstrated further that normal adult
hepatocytes can be serially transplanted through seven genera-
tions of FAH null mice with each transplanted cell undergoing an
average of 69 or more divisions [15]. Therefore, under selected
circumstances, the proliferative capacity of mature hepatocytes
is virtually infinite.
In other rodent models of liver repopulation by transplanted
cells, host hepatocytes have been rendered incapable of
proliferation by DNA damage through treatment with DNA
alkylating agents, retrorsine [16] or monocrotaline [17], or by
X-irradiation, using a Phillips orthovoltage irradiator [18,19].
Other studies have used genetically modified p27 null mouse
hepatocytes exhibiting increased proliferative activity [20] or
Bcl-2 transgenic mouse hepatocytes that are resistant to
apoptosis [21], in conjunction with repeated host liver injury
by carbon tetrachloride (CCl4) administration or anti-Fas
antibody administration to stimulate liver regeneration. All of
these models exhibit two critical features: 1) extensive and
continuous or repeated liver injury and 2) a selective
advantage for transplanted cells to proliferate and/or survive
compared to host hepatocytes. It has also been shown recently
in rats that hepatocytes can differentiate into cholangiocytes
and form mature bile ducts, when there is massive bile duct
injury [22]. Thus, hepatocytes fulfill all the criteria for stem
cells. However, transplanted hepatocytes do not significantly
repopulate the normal (or near normal) adult liver [23,24] and
therefore do not behave as stem cells under normal
circumstances.
4. Hepatic stem cells in the adult liver?
Studying liver regeneration in mice after severe nutritional
injury in the late 1950's, Wilson and Leduc observed that non-
parenchymal cells of the distal cholangioles proliferate and,
after cessation of injury, differentiate into hepatocytes andpossibly into new interlobular bile ducts and they proposed that
there may be stem cells in the adult liver [25]. During the same
period, it was established that hepatocytes and bile duct
epithelial cells are of common embryonic origin and it was
proposed that hepatocytes are derived from epithelial precursors
in the distal cholangioles [26,27]. However, specific identifica-
tion of these cells has not been possible, because unique liver
stem cell markers are not currently available. Nonetheless,
numerous studies during the last decade have identified cells
both within and outside the liver that exhibit properties of
hepatic stem cells and can differentiate into hepatocytes and/or
bile duct epithelial cells both in culture and after their
transplantation (see below).
5. “Oval cells” as facultative stem cells
The term “oval cells”was first introduced by Farber [28], who
found non-parenchymal cells with a characteristic morphologic
appearance after treatment of rats with carcinogenic agents,
ethionine, 2-acetylaminofluorine (2-AAF) and 3-methyl-4-
dimethyl aminobenzene. He described these cells as “small
oval cells with scant lightly basophilic cytoplasm and pale blue-
staining nuclei” [28]. Thorgeirsson et al. subsequently showed
that “oval cells”, induced to proliferate in the periportal area by
treatment of rats with 2-AAF/PH, take up [3H] thymidine and the
[3H] thymidine labeled cells subsequently accumulate in the mid
parenchyma as clusters of basophilic hepatocytes [29]. The
expression of bile duct markers (CK-7, CK-19 and OV-6) and
hepatocytic markers (AFP and Alb) in [3H] thymidine labeled
“oval cells” over time also suggested a precursor/product rela-
tionship between “oval cells” and hepatocytes [29,30]. More-
over, the temporal pattern of liver-enriched transcription factor
expression (HNFs and C/EBPs) during “oval cell” activation in
rats by 2-AAF/PH also mirrored their expression pattern during
liver development [31]. Finally, studies showing activation of
stem cell genes, c-kit [32], CD34 [33], flt 3 receptor [34] and LIF
[35] during “oval cell” proliferation, suggested that they exhibit
stem cell-like properties.
Liver “oval cells” have been referred to as facultative stem
cells or as a reserve stem cell compartment [36,10,11]. Clearly,
the rat liver regenerates after 2-AAF/PH administration (condi-
tions under which hepatocyte proliferation is blocked) and “oval
cells” that are induced in this model differentiate into hepato-
cytes; however, the percentage of repopulation that is derived
from “oval cells” has not been determined. The finding that
“oval cells” also express hematopoietic stem cell (HSC) genes
(such as c-kit, CD34, Sca-1 and Thy-1) has led to the suggestion
that they originate from HSC [37–40]. However, several recent
studies in mice and rats have shown that transdifferentiation of
HCS into “oval cells” is a very rare event, which probably does
not have physiological significance [41–43].
6. Other models of “oval cell” activation
Cells with the morphologic appearance of “oval cells” are
also induced to proliferate in rodents by a number of other
regimens: administration of a choline-deficient (CD) diet
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with other DNA alkylating agents; 1,4-bis[N,N′-di(ethylene)-
phosphamide]piperazine (Dipin) [44] or 12,18-dihydroxy-
senecionan-11-16-dione (retrorsine) in combination with PH in
rats [45], feeding 3,5-diethoxycarbonyl-1,4-dihydrocollidine
(DDC) in mice [46], phenobarbital/cocaine induced liver injury
in mice [47], acute allyl alcohol toxicity in rats [48] or D-
galactosamine administration in rats, which temporarily blocks
hepatocyte proliferation [49,50].
7. Transplantation of “oval cells”
The most important property that would establish “oval
cells” as liver stem cells would be restoration of liver mass after
their transplantation. Isolated “oval cells” and “oval cell” lines
have been transplanted into the liver of normal, carcinogen-fed
or metabolically defective rats or mice. More than 15 years ago,
it was reported that “oval cells” isolated from the liver of rats fed
a CD/2-AAF diet produced colonies, i.e. clusters of cells with a
phenotype resembling hepatocytes, in the livers of rats fed the
same diet but not in recipients receiving a normal diet [51].
However, the level of liver repopulation by these “colonies”was
not determined. An epithelial cell line originating from normal
rat liver (WB-344), that exhibits stem cell properties in vitro
[52], also showed very little capacity to repopulate the liver
when transplanted into syngeneic rats [53]. “Oval cells” isolated
from the liver of D-galactosamine treated rats also engraft and
undergo 5–7 rounds of cell division, as opposed to adult hepa-
tocytes that undergo no more than 2–3 cell divisions under the
same conditions [54]. This augmented proliferation, however,
was not sufficient for “oval cells” to significantly repopulate the
normal adult liver.
“Oval cells” isolated from the liver of Long–Evans Cinna-
mon (LEC) rats and transplanted into LEC or Nagase analbu-
minemic rats, also displayed an hepatocytic phenotype and
produced albumin (Alb) [55], but, once again, liver repopula-
tion was low. However, “oval cells”, isolated from the livers of
DDC-fed mice and transplanted into FAH null mice, repopulate
the metabolically compromised liver very well, i.e. at least as
efficiently as mature hepatocytes [41]. “Oval cells” from GFP
transgenic mice, maintained on a DDC diet, were isolated by
selection on immunomagnetic beads (MACS), using the surface
marker Sca-1 [56]. These “oval cells” were transduced with
human α1-antitrypsin (α1-AT) and transplanted into monocrota-
line-treated C57BL/6 mice in conjunction with PH. In this
model, there was 40–50% liver repopulation by GFP expressing
cells, of which 5–10% also expressed human α1-AT [56]. These
latter studies show that substantial liver repopulation can be
achieved with “oval cells”, but, as with hepatocytes, this re-
quires extensive modification of the host liver.
8. Thy-1+ cells
In 1998, Petersen et al. [37] identified expression of Thy-1 by
“oval cells” in the rat 2-AAF/CCl4 model of liver injury/re-
generation. Since Thy-1 is normally expressed by hematopoietic
stem and progenitor cells, they subsequently transplanted bonemarrow (BM) cells into rats and mice, preconditioned by BM
ablation, and showed the presence of donor BM derived
hepatocyte-like cells in the recipient liver [40]. Avital et al.
[57] subsequently isolated β2-microglobulin
−/Thy-1+ cells from
the BM of rats that had undergone bile duct ligation and showed
hepatocytic gene expression of these cells in culture and
differentiation into hepatocytes after their transplantation. In
more recent studies, it has been reported that Thy-1+ cells
isolated from the rat BM repopulate the liver under conditions of
severe hepatocyte growth inhibition, together with a liver re-
generative stimulus (monocrotaline/BM transplantation/2-AAF/
PH), but once again the levels of liver repopulation were still low
[58]. Thy-1+ cells have also been identified in the developing
rodent and human fetal liver [59,60]. Thy-1+ cells isolated from
rat fetal liver showed proliferative activity and express liver
specific genes in culture (CK-18, AFP and Alb) [61]. However,
these cells repopulate the liver only under severe endogenous
hepatocyte growth suppression (retrorsine/PH) [62].
9. Studies with “oval cell” lines
Stable “oval cell” lines have been established from normal
liver of Fischer (F)-344 rats [63] and from the liver of rats fed a
CD diet supplemented with DL-ethionine [63,64] or allyl alcohol
treatment [48], from livers of LEC rats, an animal model of
Wilson's disease [55], from livers of transgenic rats expressing
the Ras oncogene [65], from p53 knockout, normal or TAT-
GRE lacZ mice fed a CD, ethionine-supplemented diet [66,64]
and from human liver [67]. The common feature of these “oval
cell” lines is their ability to differentiate into cells expressing
hepatocytic or biliary epithelial cell genes in cell culture. This
suggests that they are bipotent, but in vivo transplantation
studies with these cell lines are again very limited.
10. Hepatic stem cells in the fetal liver
In the mouse, endodermal stem cells begin to proliferate
when the ventral wall of the endoderm becomes positioned next
to the developing heart on embryonic day (ED) 8.0 [26,68–70].
Specification toward the hepatic epithelial lineages occurs at
ED8.5 and requires fibroblast growth factor (FGF) signaling
from the cardiogenic mesoderm [71] and bone morphogenic
protein (BMP) signaling from the septum transversummesench-
yme [72]. By ED9.0–9.5, these cells begin to express GATA4
and liver-enriched, nuclear factor HNF4α, as well as liver-
specific genes, AFP followed by Alb [70,73]. These events
occur one day later in the rat. The hepatic-specified cells are now
referred to as hepatoblasts and proliferate massively. Cords of
hepatoblasts invade the septum transversum mesenchyme that
contains stellate cells and sinusoidal endothelial cells. These
cells secrete a variety of cytokines and growth factors, such as
EGF, FGF, HGF, TGFβ, TNFα and IL-6, that are known to be
involved in liver development, as well as in the hepatocyte
proliferative response during liver regeneration [70,11].
At ED11 in the rat, HSC invade the liver bud to form a
visible liver structure that is primarily an hematopoietic organ.
Hepatoblasts continue to expand rapidly and begin to express
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CKs-14, 8 and 18 and γ-glutamyl-transpeptidase (GGT), and
later α1-AT, glutathione-S-transferase (GST)-P and fetal iso-
forms of aldolase, lactic dehydrogenase and muscle pyruvate
kinase (M2-PK) [74–77]. Just prior to ED16, hepatoblasts di-
verge along two lineages, hepatocytes and cholangiocytes
[73,78,79]. Differentiation along the cholangiocytic lineage is
promoted by Notch signaling and is antagonized by HGF, which
in conjunction with oncostatin M promotes hepatocytic differ-
entiation [80]. After ED16, there is a massive change in the gene
expression profile of rat fetal liver epithelial cells to a more
differentiated phenotype [81] and the percentage of bipotent
cells, i.e., those expressing genes in both the hepatocytic and
cholangiocytic lineages (e.g., AFP or Alb and CK-19, respec-
tively), is markedly reduced [78,79,82,24]. At this point, most
of the cells are unipotent and irreversibly committed to either
the hepatocytic or cholangiocytic lineage [79,24]. As organo-
genesis proceeds, intrahepatic bile ducts are formed in the
vicinity of large portal vein branches, beginning on ∼ED17
[83]. The basic lobular structure is now completed, although the
parenchymal cords do not become fully mature until several
weeks after birth.
11. Bipotential cells and cell lines generated from rodent
fetal liver
Single cells that are RT1A1−/OX18low/ICAM-1+ have been
isolated from rat ED13 fetal liver by Kubota and Reid [84].
These cells are clonogenic in culture and exhibit bipotential
differentiation, producing epithelial colonies expressing CK-19,
Alb or both proteins. Suzuki et al. [85] isolated highly proli-
ferative cells from mouse liver (Ter119−/CD45−/c-kit−/CD29+/
CD49f+), termed hepatic colony-forming-units (H-CFU-C), that
showed hepatocytic and biliary lineage markers in cell culture.
They subsequently isolated H-CFU-C as single cells by flow
cytometry and these cells exhibited bipotential differentiation
in vivo [86]. These cells also exhibited pancreatic, gastric and
intestinal epithelial differentiation in vitro and in vivo and were
regarded as endodermal stem cells, although their ability to
repopulate the liver was very low. Specific surface markers
for mouse hepatoblasts have also been identified: Liv2 [87],
E-cadherin [88] and Dlk-1 [89], and it has been shown that all of
these markers identify a population of AFP+/Alb+/Pan-CK+/
Sca-1+/c-kit−/CD34−/CK-19− hepatoblasts at ED12.5 [90].
Both E-cadherin and Dlk-1 can be used to purify fetal hepa-
toblasts by immunomagnetic beads or flow cytometry [88–90].
Most recently, Neighbor of PuncE11 (Nope), a cell surface gene
similar to neogenin, that is expressed during transition of cells
from an undifferentiated to a differentiated cell phenotype [91],
has been identified in mouse fetal liver epithelial cells and may
serve as a specific marker for these cells [92].
Cell lines have been established from mouse embryonic
foregut at ED9.5 [93]. One of these lines, HBC-3, grows well at
low cell density and exhibits bipotential differentiation proper-
ties. This cell line also identified the importance of the Wnt
signaling pathway during hepatocytic differentiation [94]. After
introduction into mouse blastocysts, HBC-3 cells are incorpo-rated into most tissues of the body and maintain their hepatic
epithelial phenotype [95]. Using transgenic mice expressing a
constitutively active truncated human Met receptor (c-met), met
murine hepatocyte (MMH) cell lines have been established
from mouse ED14.5 fetal livers and neonatal liver [96]. These
MMH cell lines were subsequently subcloned, producing cells
with an epithelial morphology expressing liver-enriched tran-
scription factors (LETF+) (HNF1α and HNF4), as well as E-
cadherin and Zo-1, but not expressing Alb, TTR or β-fibri-
nogen. Cells with a fibroblastic appearance, termed palmate
cells, were essentially negative for all hepatic epithelial markers
but surprisingly gave rise to epithelial clusters or bile duct-like
structures when cultured under selective differentiation condi-
tions [97].
Bipotential cell lines have also been established from non-
transgenic mouse embryonic and adult liver (BMEL and
BMAL, respectively) that exhibit bipotential capacity in vitro
and participate in liver regeneration in uPA/SCID mice in vivo
[98,99]. These cell lines exhibit some properties of stem cells
including: 1) clonality, 2) bipotential differentiation, 3) high
proliferative capacity in culture, and 4) ability to differentiate
into mature hepatocytes and bile duct cells in vivo. However,
despite the fact that these cells grow very well in culture and can
be readily passaged, they produce significant liver repopulation
only under conditions of massive liver injury and preferential
selection of transplanted cells, the same conditions that allow
liver repopulation by adult hepatocytes [13,14]. It is thought
that this may reflect a low engraftment efficiency. However, in
the early 1990s, Grisham et al. reported in rats that the host liver
exerts an anti-proliferative and anti-tumor effect on trans-
planted, chemically transformed WB-344 cells and that this
effect decreases with age of the host recipient [100].
12. Epithelial-to-mesenchymal transition (EMT)
The palmate cells, originally described in mice by Weiss et al.
[97], probably represent an epithelial-to-mesenchymal transition
(EMT), a process that is now well-known in cultured cells.
Cultured fetal rat hepatocytes have been shown to undergo EMT
when treated with TGFβ or fetal bovine serum [101]. These cells
express high levels of vimentin and Snail and lose expression of
CK-18 and E-cadherin. Both hepatic stellate cells and cultured
human hepatic epithelial progenitor cells undergo EMT in culture
[102]. Most recently, primary adult hepatocytes were shown to
undergo EMT, also when cultured with TGF-β1 [103]. Co-
expression of hepatic epithelial and hematopoietic stem and
progenitor cell markers by adult rat or human BM-derived cells in
culture, such as c-kit, CD34 and Thy-1, may also represent EMTs
[104,105]. The reverse process, i.e. mesenchymal-to-epithelial
transition (MET), has also been reported with cells derived from
human islets that first undergo EMT when cultured in serum
containing medium to produce fibroblast-like cells, which then
proliferate very well [106]. By simply switching to serum-free
medium, these cells can be reconverted from fibroblast-like cells
into proinsulin and proglucagon producing islet-like cells (MET).
EMT is also known to occur in vivo during remodeling of
tissues in early embryogenesis [107,108] and recent studies in
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tion of the mesoderm may be derived from a bipotential layer of
cells called mesendoderm [109]. EMT has been reported in fetal
liver in stromal cells that express both mesenchymal and epi-
thelial markers [102]. What is most interesting is that EMT of
hepatocytes to fibroblasts has been clearly demonstrated in vivo
by lineage tracing studies in lacZ transgenic mice chronically
treated with CCl4 [103]. In these studies, almost 50% of fib-
roblasts observed in CCl4-induced hepatic fibrosis were derived
from hepatocytes by EMT, although it is possible that the cells
undergoing EMT were hepatocyte progenitor cells. These find-
ings have significant implications in terms of the pathogenesis
of chronic liver disease.
13. Stem cell properties of primary rat fetal liver
epithelial cells
As indicated previously, the ultimate test for a putative stem
cell is to demonstrate its ability to self-renew in vivo and to
functionally repopulate a tissue or organ, long-term (properties
that have been shown repeatedly with hematopoietic stem cells).
Sandhu et al. [24] reported 5–10% repopulation of DPPIV−
mutant F344 rat liver by transplanting wt ED14 fetal liver
epithelial cells in conjunction with two-thirds PH. Liver repo-
pulation by transplanted cells increased progressively over six
months, and the bulk of repopulating clusters contained both
hepatocytes and mature bile ducts. The transplanted cells were
integrated into the host parenchyma and formed hybrid bile
canaliculi with host hepatocytes. Thus, transplanted rat ED14
fetal liver epithelial cells exhibited three major properties of liver
stem cells, 1) extensive proliferation, 2) bipotency and 3) long-
term repopulation in vivo [24]. Liver repopulation by trans-
planted rat fetal liver cells was achieved in a non-selective host
liver environment but required PH to initiate the process. Using
greater numbers of unfractionated rat ED14 fetal liver cells,
Oertel et al. [110] achieved 23.5% replacement of liver mass at
6months under the same non-selective conditions. Repopulation
continues to increase for up to one year, reaching an average of
~30% for the total liver (Fig. 2; Oertel et al., unpublished data).
This represents greater than 1000-fold amplification of trans-
planted fetal liver epithelial cells in the host organ. The
mechanism for liver repopulation by rat fetal liver stem/
progenitor cells is cell competition [110], a process originally
described in Drosophila during wing development [111,112].
However, self-renewal or serial transplantability has not yet been
demonstrated with these cells, and thus they have been termed
“fetal liver stem/progenitor cells” (FLSPC) [110]. These cells
have been crypreserved with full ability to repopulate the normal
adult liver after thawing [113] andmost recently, rat FLSPC have
been enriched to 95% purity by immunoselection [114].
14. Liver repopulation by extrahepatic and
embryonic stem cells
Various studies have reported that cells from the BM are
released into the circulation, migrate to the liver and differentiate
into hepatocytes. However, the extent to which this occurs andthe mechanism(s) involved remain highly controversial [for
reviews, see [115–117]]. Estimates of liver repopulation by
hematopoietic cells vary widely, ranging from b0.01% to 40%
[40,118–128]. Originally, Petersen et al. reported that BM stem
cells from DPPIV+ F344 rats transplanted into sublethally
irradiated DPPIV−F344 rats repopulate the BM and then migrate
to the liver and “transdifferentiate” into hepatocytes by entering
the liver “oval cell” progenitor pathway [40]. This mechanism
was generally accepted until the studies ofWang et al. [41] using
lacZ marking, showed that BM cells did not enter the “oval cell”
pool in wt mice treated with DDC or contribute to liver repo-
pulation by “oval cells” in secondary FAH−/− mouse recipients,
and Dabeva et al. [42] showed in rats that DPPIV+ BM cells
transplanted into DPPIV− rats contributed less than 1% to “oval
cells” expanded by 3 different methods: 1) 2-AAF/PH, 2) re-
trorsine/PH or 3) D-galactosamine-induced liver injury.
In FAH−/− mice and other model systems, it has been shown
that cell fusion, rather than transdifferenitation, represents the
mechanism whereby hematopoietic cells acquire an hepatocytic
phenotype. Initial studies in cell culture revealed that BM and
neuronal cells can fuse with ES cells [129,130].Wang et al. [131]
and Vassilopoulos et al. [132] subsequently showed that hema-
topoietic stem cells fuse with hepatocytes in FAH null mice to
produce cells expressing the deficient enzyme, which then ex-
pand massively to restore liver mass and function [131,132].
Fusion also occurs between hematopoietic cells and neurons or
muscle cells [133,134] and it has been shown that myelomo-
nocytic cells can fuse with hepatocytes [135,136] or muscle cells
[137] to produce somatic hybrids expressing genes from both
parental cell types.
However, in other studies reported during the same period,
fusion did not appear to be required for BM-derived cells to
differentiate into hepatocytes [138–140]. In two of these studies,
transplanted BM-derived cells are scattered sparsely throughout
the hepatic parenchyma, repopulation clusters are very small and
total liver repopulation is low. However, in the third study, Jang
et al. [140] reported much higher levels and rapid liver repo-
pulation using a specific subpopulation of HSC that were pre-
homed to the BM, reisolated and then transplanted into the liver.
When BM pre-homed HSC were placed in a culture chamber
over minced tissue from CCl4-injured liver, separated by a
0.4 μm pore size membrane in a trans-well apparatus, these cells
exhibited many hepatocytic gene expression characteristics
[140]. After transplantation of BM pre-homed HSC into mice
pretreated with CCl4 to induce liver regeneration, there was
7.6% liver repopulation in one week. This finding was most
surprising, as it required nearly 100% engraftment efficiency of
pre-homed cells, approximately 7 divisions of transplanted cells
and no loss of transplanted cells or their progeny during the
regenerative process.
Other studies have transplanted unfractionated or CD34+
enriched cells from human cord blood [141–144], multipotent
adult progenitor cells (MAPC) [145,146] or mesenchymal stem
cells [147–152] into the liver of immunodeficient mice that
subsequently express a differentiated hepatocytic phenotype
[141–152]. However, liver repopulation by these cells is also
very low. Several recent studies report that mesenchymal stem
Fig. 2. Experimental design used to show repopulation of the rat liver by fetal liver stem/progenitor cells. Cells isolated from wt (DPPIV+) ED14 F344 rat liver are
transplanted into the liver of adult DPPIV−mutant F344 rats immediately after two-thirds PH and repopulation is followed over time by enzyme histochemistry for
DPPIV.
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along the hepatocytic lineage, can also engraft in the liver
parenchyma and contribute to liver regeneration [153,154]. In
one of these studies [154], large repopulation clusters were
obtained with hepatocyte-differentiated mesenchymal stem
cells, but this required retrorsine treatment. These studies are
promising, but the ability of mesenchymal stem cells to
repopulate the adult liver under more normal, clinically viable
circumstances will need to be established. Similarly, it has been
reported that ES cells can be induced along the endodermal and
hepatocytic lineages in culture [155–162], and then trans-
planted into the liver with differentiation into both mature
hepatocytes [161,162] and bile duct epithelial cells [162]. The
levels of liver repopulation obtained with hepatocyte-differ-
entiated ES cells are also low, but somewhat higher when
transplanted into MUP-uPA/SCID mice [162]. However, it is
hoped that conditions will be developed in the future in which
lineage-specified ES cells will be therapeutically effective.In GFP transgenic mice transplanted with a wt liver, it has
been shown that extrahepatic cells, expressing stem cell
markers c-kit and Sca-1, enter the liver and continue to
express these genes, as well as liver progenitor cell markers,
A6 and human specific antigen [163]. Overall, GFP+ cells
comprised 9% of cells in periportal areas at 28 days after
transplantation of an undersized, but not a normal size graft.
However, at present, it is unclear what % of GFP+ cells were
hepatocytic. These experiments are reminiscent of cross gender
studies in humans in which males with end stage liver disease
received transplants of female livers [119,120]. The presence
of extrahepatic-derived male cells in the female liver
(presumably of hematopoietic origin) was documented by Y-
chromosome in situ hybridization in mice and humans and it
was reported that the cells containing Y-chromosomes were
hepatocytes [118–121,123]. However, fluorescence in situ
hybridization (FISH) is very difficult technologically, and it is
difficult to quantify this process and determine the specific
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cells in the liver.
15. Other roles for BM and mesenchymal cells in
liver regeneration
Recent studies have discovered that BM stem cells may play
a major role in either generation or resolution of hepatic fibrosis,
as well as in liver regeneration following acute or chronic liver
injury. Forbes and colleagues observed that a substantial pro-
portion (6.8–22%) of myofibroblasts in human liver scar tissue
are of extrahepatic (BM) origin [164]. Subsequently, studies in
mice showed that the contribution of BM cells to parenchymal
regeneration is minor (0.6%), whereas the BM contributed
extensively to the hepatic stellate (68%) and myofibroblast
(70%) cell populations [165]. Moreover, in mice myofibroblasts
in the liver originate largely from mesenchymal stem cells and
macrophages derived from the BM, and these myofibroblasts
coordinate both production of hepatic fibrosis and liver injury
and resolution of fibrosis during recovery from inflammatory
liver injury [166].
Other studies have reported that injections of BM-derived
stem cells can stimulate liver regeneration and restore liver
function during chronic liver injury by enhancing the
degradation of liver fibrosis in mice [167,168]. Such events
are associated with induction of metalloproteinases, especially
MMPs 2, 9, and 13 [169]. Most recently, it has been reported
that BM-derived endothelial progenitor cells (EPCs), injected
into the spleen during liver injury, engraft in the liver, form
new blood vessels and secrete growth factors, such as HGF,
TGFα, EGF and VEGF, that stimulate liver regeneration andFig. 3. Schematic diagram summarizing the various stem or progenitor-like cells that
hepatocytic or bile ductular phenotype. (FLSPC = fetal liver stem/progenitor cells, HS
stem).improve survival of animals with massive liver injury [170].
Thus, the role of BM stem cells in liver regeneration may be
supportive in generating new parenchymal mass and, under
some circumstances, in ameliorating hepatic fibrosis. Similar
mechanisms have been reported in mice to be responsible for
improved cardiac function following transplantation of BM
cells [171].
16. Human “oval cells” and stem cells
A human counterpart to “oval cell” activation has been
described in liver tissue obtained from patients with extensive
chronic liver injury or submassive hepatic necrosis, i.e. the so-
called “ductular reaction” (for a detailed description, see ref.
[172]). In very simple terms, “ductular reactions” are comprised
of collections of cells in ductular arrays with the morphologic
appearance and immunohistochemical markers comparable to
those found in rodent “oval cells”. They are present primarily in
the portal tracts and extend into the parenchyma expressing both
hepatocytic and bile ductular markers, as well as certain neuro-
endocrine genes [173–175]. Using simultaneous double and
triple immunohistochemistry, Zhou et al. [176] have most re-
cently shown that “ductular reactions” are bipolar structures
with cells at one pole exhibiting hepataocytic morphology and
gene expression (HepPar1 or HepPar1/NCAM) and cells at the
other pole exhibiting biliary morphology and gene expression
(CK-19 or CK-19/NCAM), with undifferentiated epithelial cells
in the center expressing only NCAM. Cells with similar mor-
phologic and immunohistochemical properties have also been
identified in the human fetal liver beginning at 4 weeks ges-
tation [177].have been transplanted into rats or mice, producing progeny exhibiting either an
C = hematopoietic stem cells, MSC = mesenchymal stem cells, ES = embryonic
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saged human fetal liver epithelial cells with bipotent properties,
and several of these studies have demonstrated their differentia-
tion into hepatocytes after transplantation into SCID or nude
mice [178–180]. Schmelzer et al. [181] have most recently
identified two populations of hepatic progenitor cells from
human fetal, neonatal and pediatric liver that exhibit stem cell
properties. One population is thought to represent an hepatic stem
cell (AFP−/Alb+) and the other a slightly more differentiated
hepatoblast (AFP+/Alb+). In a most recent study, Schmelzer et al.
[182] report data suggesting that these cells may reside in the
Canals of Hering and in culture, they can differentiate into
hepatoblasts, possibly requiring cues from companion cells that
copurify with them during immunoselection. One curious ques-
tion, which remains unanswered, is that the presumed hepatic-
specified stem cells in human neonatal, pediatric and adult liver
are Alb positive but AFP negative, which is precisely opposite to
what one might expect based on expression of AFP before Alb
during liver development [73]. Nonetheless, these studies sug-
gest that a human liver somatic stem cell might exist and hope-
fully future studies will demonstrate in vivo self-renewal and
long-term repopulation of the liver by these cells, proving that
they are indeed stem cells.
In summary, considerable advances have been made in
identifying cells in the fetal, neonatal and adult liver with stem-
cell properties. Cell lines have also been established, including
ES cells, fetal liver cells, and oval (progenitor) cells that also
exhibit stem cell properties and differentiate into hepatocytes
and/or bile ducts in vitro and in vivo (Fig. 3). However, all of
these cells and cell lines have shown only limited repopulation
of the normal liver at the current state-of-the-art, except for rat
fetal liver stem/progenitor cells that produce substantial long-
term replacement and function. In order to further advance the
field of liver cell therapy, it will be necessary to find conditions
under which cells and cell lines derived from ES, fetal liver or
adult liver, can be expanded in culture and successfully
repopulate the liver under conditions that will be clinically
acceptable. Such cell therapy can be readily visualized for
treatment of inborn metabolic disorders, as well as chronic liver
diseases of various etiologies.
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